Funding transnational collaborative research through joint transnational calls is one of the major objectives of E-Rare. This is the most important and effective joint activity to enhance the cooperation between European scientists working on rare diseases and thus reducing the fragmentation of research in this field. E-Rare launches calls on a yearly basis. The topic and eligibility criteria are specified every year and therefore may vary from one call to the other.

France
Germany
Greece
GETHERTHAL
Improvements of vector technology and safety for the gene therapy of thalassemia

Project Coordinator

University of Athens School of Medicine and Foundation for Biomedical Research of the Academy of Athens Basic Medical Sciences
Athens
Greece

Partners

Christof von Kalle DKFZ/NCT Heidelberg Translational Oncology Heidelberg, Germany
François-Loïc Cosset ISERM U758 Human Virology Lyon, France

Publications of the GETHERTHAL project

 

This project aims to further improve the technology of gene therapy for thalassemia as well as to prepare the ground for future clinical trials in the gene therapy field. Gene therapy utilizing lentiviral vectors (LVs) is considered as a real therapeutic alternative for many hemopoietic inherited diseases, such as beta-thalassemia. A major limitation of current LVs is their inability to govern efficient gene transfer into quiescent cells, such as human CD34+ cells that reside in the Go phase of the cell cycle. Additional problems of these vectors are the low titers observed due to regulatory elements of the beta-globin locus, such as the LCR, used in order to improve the transgene’s expression and reduce silencing, as well as the toxicity posed on CD34+ cells due to usage of VSV-G as an envelope protein. These facts hamper their application for gene therapy of hematopoietic cells. Thus, the major current drawbacks affecting therapeutic efficacy, include 1) insufficient transduction efficiency of the target hemopoietic stem cells, 2) inconsistent expression of the transgene and lack of long term expression due to silencing and 3) putative aberrant expression near integration sites raising safety issues. To this end, the current proposal aims to address comprehensively specific issues of the globin gene therapy, by the 1) improvement of current vector technology, 2) development of novel strategies for cell targeting and finally 3) establishing an extensive genotoxic study for the generation of a cell model that will permit and predict patient safety for future clinical trials.

E-Rare 2012 - Created by Toussaint Biger